Global demand for Antiviral Drugs Treatment market was valued at approximately USD 56.2 billion in 2019, and is expected to generate revenue of around USD 65.90 billion by end of 2026, growing at a CAGR of around 2.3% between 2019 and 2026.
The report covers forecast and analysis for the Antiviral Drugs Treatment market on a global and regional level. The study provides historic data from 2016 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Billion). The study includes drivers and restraints for the Antiviral Drugs Treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Antiviral Drugs Treatment market on a global level. In order to give the users of this report a comprehensive view on the Antiviral Drugs Treatment market we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Drug Class, Type, Application, and regional segments are benchmarked based on their market size, growth rate and general attractiveness.
Viral infections have caused millions of human casualties worldwide across human history, prompting the production of antiviral drugs in urgent need. A new period of antiviral drug production began in June 1963, when the first antiviral medication, idoxuridine, was approved. Antiviral drugs pertain to the class of medicines that have been used to treat viral infections including HIV, measles, hepatitis, and influenza. In general such medications are distributed in the form of vaccines. Moreover, most of these medications are used for common viral infections, while some (full-spectrum antiviral drugs) are effective against a large range of viruses.
The study provides a decisive view on the Antiviral Drugs Treatment market by segmenting the market based on Drug Class, Type, Application, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2020 to 2026. Based on Drug Class, the market is segmented into DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors and Others.
Based on Type, the market is segmented into Branded, and Generic. Based on Application, the market is segmented into HIV, Hepatitis, Herpes, Influenza, and Others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Geographically speaking, North America dominated the Antiviral Drugs Treatment market with a share of about 37.22% in 2019. The key players’ presence in the region, convenience of refined healthcare infrastructure, and cumulative awareness of viral diseases has led to increased demand for Antiviral drugs in North America region.
Growing occurrence of viral infections such as HIV, hepatitis, respiratory syncytial virus (RSV), and influenza is projected to boost the demand for antiviral drugs. Hepatitis B, for example, has caused about 987,000 deaths in 2017 according to data released by the WHO. In addition, in 2017 about 287 million patients were reported to have been infected with hepatitis B virus (HBV) infection. This is expected to drive the demand for efficient treatment solutions such as antiviral drugs.
Key players within global Antiviral Drugs Treatment market include Gilead Sciences; F. Hoffmann-La Roche AG; GlaxoSmithKline plc; AbbVie; Merck & Co., Inc.; Johnson & Johnson Services, Inc.; Bristol-Myers Squibb Company; Cipla Inc.; Aurobindo Pharma; and Dr. Reddy’s Laboratories Ltd. & Co., Inc and others.
The report segments global Antiviral Drugs Treatment market as follows:
Global Antiviral Drugs Treatment Market: Drug Class Segment Analysis
Global Antiviral Drugs Treatment Market: Type Segment Analysis
Global Antiviral Drugs Treatment Market: Application Segment Analysis
Global Antiviral Drugs Treatment Market: Regional Segment Analysis